Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) CRO Marcus Jewell sold 9,928 shares of the firm’s stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $10.66, for a total value of $105,832.48. Following the transaction, the executive directly owned 404,345 shares in the company, valued at approximately $4,310,317.70. The trade was a 2.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Marcus Jewell also recently made the following trade(s):
- On Monday, November 16th, Marcus Jewell sold 12,462 shares of Cellebrite DI stock. The shares were sold at an average price of $11.55, for a total value of $143,936.10.
- On Thursday, November 12th, Marcus Jewell sold 393 shares of Cellebrite DI stock. The shares were sold at an average price of $13.31, for a total value of $5,230.83.
- On Friday, August 21st, Marcus Jewell sold 12,562 shares of Cellebrite DI stock. The shares were sold at an average price of $11.24, for a total value of $141,196.88.
Cellebrite DI Stock Up 1.4%
NASDAQ:CLBT opened at $11.32 on Friday. The stock’s 50 day moving average price is $11.57 and its 200 day moving average price is $13.14. The company has a market capitalization of $2.82 billion, a PE ratio of 33.82, a P/E/G ratio of 1.41 and a beta of 1.06. Cellebrite DI Ltd. has a 52-week low of $9.58 and a 52-week high of $19.39.
Hedge Funds Weigh In On Cellebrite DI
A number of hedge funds and other institutional investors have recently made changes to their positions in CLBT. Connors Investor Services Inc. lifted its position in Cellebrite DI by 23.0% during the 3rd quarter. Connors Investor Services Inc. now owns 216,241 shares of the company’s stock worth $2,435,000 after acquiring an additional 40,474 shares during the period. Advisors Asset Management Inc. acquired a new position in shares of Cellebrite DI in the third quarter valued at approximately $334,000. Portolan Capital Management LLC increased its holdings in shares of Cellebrite DI by 1.8% in the third quarter. Portolan Capital Management LLC now owns 1,967,445 shares of the company’s stock valued at $22,153,000 after purchasing an additional 34,931 shares during the period. Aquatic Capital Management LLC acquired a new position in shares of Cellebrite DI in the third quarter valued at approximately $1,870,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Cellebrite DI by 36.2% during the third quarter. Goldman Sachs Group Inc. now owns 806,357 shares of the company’s stock worth $9,080,000 after purchasing an additional 214,515 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. reduced their price objective on Cellebrite DI from $16.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, November 13th. Needham & Company LLC raised their target price on shares of Cellebrite DI from $12.50 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, November 12th. Weiss Ratings raised shares of Cellebrite DI from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, November 13th. Lake Street Capital reduced their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Finally, DA Davidson reiterated a “buy” rating and set a $15.00 price target on shares of Cellebrite DI in a research note on Tuesday, September 15th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.75.
Check Out Our Latest Research Report on CLBT
Cellebrite DI Company Profile
Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.
Featured Articles
- Five stocks we like better than Cellebrite DI
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
